
    
      Part 1 of this study (Day 1 to Day 7) is the double-blind period in which participants
      receive either ISL, DOR, DOR/ISL, or placebo. Part 2 of this study (Day 8 to Week 97) is the
      open-label period in which all participants receive DOR/ISL + optimized background therapy
      (OBT).
    
  